Sorrento Therapeutics, Inc. License Agreements
13 Contracts & Agreements
- Exclusive License Agreement, dated as of March 4, 2021, by and between Sorrento Therapeutics, Inc. and the Icahn School of Medicine at Mount Sinai (Filed With SEC on May 5, 2021)
- License Agreement, dated as of October 12, 2020, by and between Sorrento Therapeutics, Inc. and Personalized Stem Cells (Filed With SEC on February 19, 2021)
- Patent and Know-How License Agreement, dated as of September 8, 2020, by and between Sorrento Therapeutics, Inc. and Mayo Foundation for Medical Education and Research (Filed With SEC on November 9, 2020)
- Exclusive License Agreement, dated as of July 23, 2020, by and between Sorrento Therapeutics, Inc. and The Trustees of Columbia University in the City of New York (Filed With SEC on November 9, 2020)
- License Agreement, dated as of July 13, 2020, by and between Sorrento Therapeutics, Inc. and ACEA Therapeutics, Inc (Filed With SEC on November 9, 2020)
- License and Transfer Agreement dated August 15, 2017 by and among Sorrento Therapeutics, Inc., TNK Therapeutics, Inc. and Celularity, Inc (Filed With SEC on November 9, 2017)
- EXCLUSIVE LICENSE AGREEMENT (Filed With SEC on March 15, 2016)
- EXCLUSIVE LICENSE AGREEMENT (Filed With SEC on November 16, 2015)
- BINDING TERM SHEET FOR LICENSE BETWEEN CYTOLUMINA/FETOLUMINA AND TNK THERAPEUTICS (Filed With SEC on November 16, 2015)
- EXCLUSIVE LICENSE AGREEMENT (Filed With SEC on August 7, 2015)
- Exclusive License and Development Agreement between Sorrento Therapeutics, Inc. and China Oncology Focus Limited 1 (Filed With SEC on November 4, 2014)
- LICENSE AGREEMENT by and between THE SCRIPPS RESEARCH INSTITUTE, a California nonprofit public benefit corporation and SORRENTO THERAPEUTICS, INC., a Delaware corporation (Filed With SEC on May 14, 2010)
- LIMITED LICENSE AGREEMENT (Filed With SEC on September 21, 2009)
